Prolonged Use of Zoledronic ACID ( 4 years) Did Not Improve Outcome In Multiple Myeloma Patients

Conclusions Although ZA did not improve OS in patients with MM; continue to be useful to reduce skeletal events, thus improving better quality of life to the setting of patients. Teaser To assess were prolonged use of zoledronic acid (ZA:4 years) improves outcome in multiple myeloma (MM)patients, we performed a clinical trial, for compared the effect of 48 and 24 months.A total of 170 patients were randomly assigned, to the two groups in the trial.The overall survival was not improved. However ,ZA retain to reduce the number of skeletal events. Thus, we suggested that ZA , will be considered to be employed for longer duration, in attempt to improve patients quality of life.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research